Multicenter Automatic Defibrillator Implantation Trial–Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol

    loading  Checking for direct PDF access through Ovid

Abstract

Patients with diabetes mellitus, prior myocardial infarction, older age, and a relatively preserved left ventricular ejection fraction remain at risk for sudden cardiac death that is potentially amenable by the subcutaneous implantable cardioverter defibrillator with a good risk-benefit profile. The launched MADIT S-ICD study is designed to test the hypothesis that post–myocardial infarction diabetes patients with relatively preserved ejection fraction of 36%-50% will have a survival benefit from a subcutaneous implantable cardioverter defibrillator.

Related Topics

    loading  Loading Related Articles